EV/EBITDA Multiple: Agape ATP Corp (ATPC)

Corporate company logo of agapeatpgroup.com (ATPC)

The EV/EBITDA price action chart for Agape ATP Corporation (ATPC) stands at 0.00. The business relies on an Asian preventive healthcare network, combining wellness services with the sale of dietary supplements. Revenues depend on distributor performance and regional economics, which creates moderate cash flow stability. Meanwhile, the holding company is currently investing almost nothing in R&D, limiting itself to the support of existing IT systems and basic supplement testing.

ATPC (Agape ATP) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/14/2026

agapeatpgroup.com (ATPC) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart Agape ATP|ATPC - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Agape ATP Corporation|ATPC - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Agape ATP|ATPC - Total Net Assets|Market Capitalization to Book Value Ratio agapeatpgroup.com|ATPC - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Agape ATP Corporation|ATPC - Long-Term Debt to Equity|Short-Term Debt to Equity Agape ATP|ATPC - Company Cumulative Debt|Debt to Book Capitalization Ratio Agape ATP Corporation|ATPC - Company Long-Term Debt|Company Short-Term Debts Agape ATP|Quick Liquidity agapeatpgroup.com
- net income and valuation multiples indicators:
ATPC - Net Financial Result|Expected Profit Agape ATP Corporation|ATPC - Price to Earnings Ratio|Forward P/E Multiple Agape ATP|ATPC - PEG Multiple|EV/EBITDA Multiple Agape ATP Corporation|ATPC - Operating profit before depreciation charges|Net earnings per share (EPS TTM) Agape ATP|ATPC - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months agapeatpgroup.com|ATPC - Earnings per share trend in current year|Earnings growth forecast for next year Agape ATP Corporation
- issuer revenue and sales details:
ATPC - Company Total Revenue|Company Future Sales Volume Agape ATP|ATPC - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Agape ATP Corporation
Initial company analysis:ATPC (Agape ATP Corp.)
Product sample of Agape ATP

To stress-test positions, it is critical for investors to evaluate a business's ability to service its debt via the ratio of enterprise value to EBITDA. Given the high customer loyalty to Agape ATP Corporation (ATPC) wellness products in Asia, the EV/EBITDA level on GURU.Markets determines how effectively cash flow covers obligations, signaling either financial stability or default risks.

Who Agape ATP Corporation competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp (ALT)|Enterprise Value to EBITDA Ratio Aardvark Pharma AARD|EV/EBITDA Multiple SGMT (Sagimet Biosciences)|EV/EBITDA Multiple bioagelabs.com BIOA|Biomea Fusion - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Quince Therapeutics (QNCX)|GUTS: EV/EBITDA Multiple|vTv Therapeutics (VTVT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pluristem Therapeutics|Synlogic Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LPCN|MTNB - Company Value to EBITDA|Spruce Biosciences - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GLTO|Carmell Corporation - EV/EBITDA Multiple|LUMO - EV/EBITDA Multiple|ONVO (Organovo) - Enterprise Value to EBITDA Ratio|RDUS: Enterprise Value to Operating Income Before Depreciation Ratio